[go: up one dir, main page]

AR066191A1 - Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona - Google Patents

Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona

Info

Publication number
AR066191A1
AR066191A1 ARP080101154A AR066191A1 AR 066191 A1 AR066191 A1 AR 066191A1 AR P080101154 A ARP080101154 A AR P080101154A AR 066191 A1 AR066191 A1 AR 066191A1
Authority
AR
Argentina
Prior art keywords
phenyl
compounds
espiro
trifluorometil
etoxi
Prior art date
Application number
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR066191A1 publication Critical patent/AR066191A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Los compuestos de la presente se pueden utilizar, por ejemplo, como compuestos inhibidores de NK-1 en preparaciones farmacéuticas y son utiles en el tratamiento de náuseas y emesis. Reivindicacion 1: Un proceso para producir un compuesto de lactama de formula 1 el proceso que comprende hacer reaccionar un compuesto de la formula 27a-sulfonato con zinc en presencia de ácido acético, formando de este modo la lactama de formula 1, donde R1 se selecciona de alquilo lineal, ramificado o cíclico que tiene hasta 6 átomos de carbono, fenilo, 2-metoxi-etilo, 2-(dimetilamino)etilo, (L)-mentilo, (D)-mentilo, dimetilamida, (R)-bencil-oxazolidinonamida, (S)-bencil-oxazolidinonamida, isobornilo, cis-pinan-2-ilo, isopinocamfeílo, adamantilmetilo, 2-adamantilo, 1-adamantilo, y (-)-8-fenilmentilo.
ARP080101154 2007-03-22 2008-03-19 Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona AR066191A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91966607P 2007-03-22 2007-03-22

Publications (1)

Publication Number Publication Date
AR066191A1 true AR066191A1 (es) 2009-08-05

Family

ID=39789180

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101154 AR066191A1 (es) 2007-03-22 2008-03-19 Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona

Country Status (11)

Country Link
US (3) US8552191B2 (es)
EP (2) EP3138836A1 (es)
JP (2) JP5451404B2 (es)
CN (2) CN104447510B (es)
AR (1) AR066191A1 (es)
CA (1) CA2682221C (es)
ES (1) ES2579771T3 (es)
HK (1) HK1136297A1 (es)
MX (1) MX2009010211A (es)
SG (1) SG182226A1 (es)
WO (1) WO2008118328A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR060303A1 (es) 2006-04-05 2008-06-04 Schering Corp Formulaciones farmaceuticas sales de 8- [1- (3,5 -bis- (trifluorometil) fenil) -etoximetil] -8-fenil-1,7 -diaza-espiro [4.5] decan -2- ona y metodos de tratamiento utilizando las mismas
HUE028908T2 (en) * 2006-04-05 2017-01-30 Opko Health Inc The hydrochloride salt of 8 - [{1- (3,5-bis (trifluoromethyl) phenyl) ethoxy} methyl] -8-phenyl-1,7-diazaspiro [4.5] decan-2-one, and process
AR066191A1 (es) 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
AU2009289598B2 (en) * 2008-09-05 2014-09-11 Opko Health, Inc. Process and intermediates for the synthesis of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl) -ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds
CN102573475B (zh) * 2009-08-14 2016-01-20 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂
GB2504076A (en) 2012-07-16 2014-01-22 Nicoventures Holdings Ltd Electronic smoking device
GB2504075A (en) 2012-07-16 2014-01-22 Nicoventures Holdings Ltd Electronic smoking device
GB201505595D0 (en) 2015-03-31 2015-05-13 British American Tobacco Co Cartridge for use with apparatus for heating smokeable material
GB201505597D0 (en) 2015-03-31 2015-05-13 British American Tobacco Co Article for use with apparatus for heating smokable material
CN105017251B (zh) * 2015-06-30 2018-06-29 齐鲁制药有限公司 一种nk-1受体拮抗剂的制备方法及其中间体
JP6384536B2 (ja) * 2015-10-23 2018-09-05 信越化学工業株式会社 フッ化イットリウム溶射材料及びオキシフッ化イットリウム成膜部品の製造方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3094522A (en) * 1961-07-25 1963-06-18 Merck & Co Inc Alkanoylthio and pyrazolo androstane derivatives
AU678409B2 (en) 1992-10-28 1997-05-29 Merck Sharp & Dohme Limited 4-arylmethyloxymethyl piperidines as tachykinin antagonists
AU682838B2 (en) 1992-12-14 1997-10-23 Merck Sharp & Dohme Limited 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperidines as tachykinin receptor antagonists
US5760018A (en) 1994-01-13 1998-06-02 Merck Sharp & Dohme Ltd. Gem-disubstituted azacyclic tachykinin antagonists
GB9601680D0 (en) 1996-01-27 1996-03-27 Pfizer Ltd Therapeutic agents
GB9626746D0 (en) 1996-12-23 1997-02-12 Knoll Ag Process
WO1998047514A1 (en) 1997-04-24 1998-10-29 Merck Sharp & Dohme Limited Use of an nk-1 receptor antagonist and an ssri for treating obesity
DE19815275B4 (de) 1998-04-06 2009-06-25 Evonik Degussa Gmbh Alkylidenkomplexe des Rutheniums mit N-heterozyklischen Carbenliganden und deren Verwendung als hochaktive, selektive Katalysatoren für die Olefin-Metathese
US6215019B1 (en) 1998-09-01 2001-04-10 Tilliechem, Inc. Synthesis of 5-decenyl acetate and other pheromone components
AU779073B2 (en) 1998-12-23 2005-01-06 Nps Allelix Corp. Indole and indolizidine derivatives for the treatment of migraine
CA2372746C (en) 1999-05-24 2012-10-02 California Institute Of Technology Imidazolidine-based metal carbene metathesis catalysts
US6858414B2 (en) * 1999-12-01 2005-02-22 BIOGAL Gyógyszergyár Rt. Multistage process for the preparation of highly pure deferoxamine mesylate salt
US6436928B1 (en) 1999-12-17 2002-08-20 Schering Corporation Selective neurokinin antagonists
CO5261559A1 (es) 1999-12-17 2003-03-31 Schering Corp Antagonistas de neurokinina selectivos
GB0004699D0 (en) 2000-02-28 2000-04-19 Merck Sharp & Dohme Chemical synthesis
WO2002014376A2 (en) 2000-08-10 2002-02-21 Trustees Of Boston College Recyclable metathesis catalysts
MXPA04004477A (es) 2001-11-13 2004-08-11 Schering Corp Antagonistas del neuropeptido neuroquinina-1(nk1).
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
WO2004004722A1 (en) 2002-07-03 2004-01-15 Schering Corporation 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related compounds as neurokinin-1(nk-1) antagonists for the treatment of emesis, depression, anxiety and cough
PL199412B1 (pl) 2002-10-15 2008-09-30 Boehringer Ingelheim Int Nowe kompleksy rutenu jako (pre)katalizatory reakcji metatezy, pochodne 2-alkoksy-5-nitrostyrenu jako związki pośrednie i sposób ich wytwarzania
CA2522946A1 (en) * 2003-04-23 2004-11-04 Merck & Co., Inc. Selective spirocyclic glucocorticoid receptor modulators
JP2007515425A (ja) * 2003-12-22 2007-06-14 シェーリング　コーポレイション 医薬組成物
US7498438B2 (en) 2004-04-07 2009-03-03 Schering Corporation Fused ring NK1 antagonists
CN101006074B (zh) 2004-07-01 2012-02-15 欧科生医股份有限公司 作为nk1拮抗剂的哌啶衍生物
JP4444745B2 (ja) 2004-07-08 2010-03-31 キヤノン株式会社 偏光分離素子および画像投射装置
US7354922B2 (en) * 2004-12-14 2008-04-08 Schering Corporation Bridged ring NK1 antagonists
TW200630380A (en) 2005-02-18 2006-09-01 Nat Univ Chung Hsing N-acylamino acid racemase of Deinococcus radiodurans and producing method thereof, and L-amino acid production method therefrom
CN102643175B (zh) 2005-07-04 2014-12-10 赞南科技(上海)有限公司 钌络合物配体、钌络合物、固载钌络合物催化剂及其制备方法和用途
HUE028908T2 (en) * 2006-04-05 2017-01-30 Opko Health Inc The hydrochloride salt of 8 - [{1- (3,5-bis (trifluoromethyl) phenyl) ethoxy} methyl] -8-phenyl-1,7-diazaspiro [4.5] decan-2-one, and process
AR060303A1 (es) 2006-04-05 2008-06-04 Schering Corp Formulaciones farmaceuticas sales de 8- [1- (3,5 -bis- (trifluorometil) fenil) -etoximetil] -8-fenil-1,7 -diaza-espiro [4.5] decan -2- ona y metodos de tratamiento utilizando las mismas
WO2007114922A2 (en) 2006-04-05 2007-10-11 Schering Corporation Salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
AR066191A1 (es) 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
AR065802A1 (es) * 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
AU2009289598B2 (en) 2008-09-05 2014-09-11 Opko Health, Inc. Process and intermediates for the synthesis of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl) -ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds
CN102573475B (zh) 2009-08-14 2016-01-20 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂

Also Published As

Publication number Publication date
ES2579771T3 (es) 2016-08-16
CN104447510A (zh) 2015-03-25
US9260428B2 (en) 2016-02-16
WO2008118328A3 (en) 2009-03-05
JP5451404B2 (ja) 2014-03-26
CA2682221A1 (en) 2008-10-02
CN101679257A (zh) 2010-03-24
WO2008118328A2 (en) 2008-10-02
US20100087426A1 (en) 2010-04-08
CN101679257B (zh) 2015-01-07
JP2014144951A (ja) 2014-08-14
EP3138836A1 (en) 2017-03-08
EP2137151A2 (en) 2009-12-30
MX2009010211A (es) 2009-10-19
EP2137151B1 (en) 2016-05-11
US10000493B2 (en) 2018-06-19
CA2682221C (en) 2017-04-25
CN104447510B (zh) 2018-03-30
SG182226A1 (en) 2012-07-30
JP2010522171A (ja) 2010-07-01
US20140024834A1 (en) 2014-01-23
US8552191B2 (en) 2013-10-08
HK1136297A1 (es) 2010-06-25
US20170008893A1 (en) 2017-01-12

Similar Documents

Publication Publication Date Title
AR066191A1 (es) Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
ECSP10010405A (es) Procesos e intermediarios para la preparacion de derivados de acido 5-bifenil-4-il-2-metilpentanoico
MX2009008781A (es) Derivados de ciclohexano espirociclicos.
MX2012006994A (es) Agente antiplaquetas novedoso.
CR10250A (es) Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
MX337714B (es) Derivado de imidazol de heteroanillo fusionado que tiene efecto de activacion de proteina cinasa activada por monofosfato de adenosina (amk).
WO2008146871A1 (ja) グルココルチコイド受容体結合活性を有する、スルホン酸エステル又はスルホン酸アミド構造を導入したフェニル基を置換基として有する新規１，２，３，４－テトラヒドロキノキサリン誘導体
MX2012015023A (es) Derivado novedoso de nicotinamida o sal del mismo.
AR060489A1 (es) Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol
MY149180A (en) Uracil compound having inhibitor activity on human deoxyuridine triphosphatase or salt thereof
EA200801828A2 (ru) Соединения 1,2,4,5-тетрагидро-3h-бензазепина, способ их получения и фармацевтические композиции, содержащие эти соединения
ATE477234T1 (de) Synthese von phenolischen estern von hydroxymethylphenolen
IN2014MN01521A (es)
NZ610705A (en) Methods of treatment using lipid compounds
NZ603465A (en) Antimalarial drug which contains 5-aminolevulinic acid or derivative thereof as active ingredient
BR112013010850A2 (pt) composto de etinilfenilamidina ou sal do mesmo, método para produzir o mesmo e fungicida para uso agrícola e em horticultura
AR084864A1 (es) Proceso de preparacion de girasa e inhibidores de topoisomerasa iv y compuestos intermediarios de dicho proceso
AR060962A1 (es) Proceso de preparacion de derivados de quinazolina e intermediarios de sintesis
MX2013007296A (es) Derivado novedoso de isoquinolina sustituido.
CO5640114A2 (es) 4-(2,4-dicloro-5-metoxifenil)amino -6-alcoxi-3-quinolincarbonitrilos para el tratamiento de lesiones isquemicas
UA111950C2 (uk) Гетероциклічні сполуки для лікування або профілактики розладів, викликаних зниженою нейротрансмісією серотоніну, норепінефрину або допаміну
MX2011012068A (es) Nucleosidos 2'-fluoro arabino y su utilizaicon.
IL201795A0 (en) Stereoisomers propofol therapeutic compounds
AR077332A1 (es) Procesos para la alquilacion de pirazoles

Legal Events

Date Code Title Description
FB Suspension of granting procedure